Miller Fisher Syndrome Following Vaccination against SARS-CoV-2

After BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination, a 30-year-old man developed bilateral lateral gaze palsy, diplopia, absent tendon reflexes, and ataxic gait. Serum anti-GQ1b and anti-GT1a immunoglobulin G (IgG) antibodies were strongly positive. Based...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamakawa, Makoto, Nakahara, Keiichi, Nakanishi, Toshihito, Nomura, Toshiya, Ueda, Mitsuharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038467/
https://www.ncbi.nlm.nih.gov/pubmed/35370249
http://dx.doi.org/10.2169/internalmedicine.8851-21
_version_ 1784693928303263744
author Yamakawa, Makoto
Nakahara, Keiichi
Nakanishi, Toshihito
Nomura, Toshiya
Ueda, Mitsuharu
author_facet Yamakawa, Makoto
Nakahara, Keiichi
Nakanishi, Toshihito
Nomura, Toshiya
Ueda, Mitsuharu
author_sort Yamakawa, Makoto
collection PubMed
description After BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination, a 30-year-old man developed bilateral lateral gaze palsy, diplopia, absent tendon reflexes, and ataxic gait. Serum anti-GQ1b and anti-GT1a immunoglobulin G (IgG) antibodies were strongly positive. Based on those findings, he was diagnosed with Miller Fisher syndrome (MFS). Intravenous immunoglobulin therapy was administered, and his symptoms fully recovered within approximately 3 months. To the best of our knowledge, this is the first report to describe the development of MFS after COVID-19 mRNA vaccination.
format Online
Article
Text
id pubmed-9038467
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-90384672022-05-06 Miller Fisher Syndrome Following Vaccination against SARS-CoV-2 Yamakawa, Makoto Nakahara, Keiichi Nakanishi, Toshihito Nomura, Toshiya Ueda, Mitsuharu Intern Med Case Report After BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination, a 30-year-old man developed bilateral lateral gaze palsy, diplopia, absent tendon reflexes, and ataxic gait. Serum anti-GQ1b and anti-GT1a immunoglobulin G (IgG) antibodies were strongly positive. Based on those findings, he was diagnosed with Miller Fisher syndrome (MFS). Intravenous immunoglobulin therapy was administered, and his symptoms fully recovered within approximately 3 months. To the best of our knowledge, this is the first report to describe the development of MFS after COVID-19 mRNA vaccination. The Japanese Society of Internal Medicine 2022-04-01 2022-04-01 /pmc/articles/PMC9038467/ /pubmed/35370249 http://dx.doi.org/10.2169/internalmedicine.8851-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Yamakawa, Makoto
Nakahara, Keiichi
Nakanishi, Toshihito
Nomura, Toshiya
Ueda, Mitsuharu
Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
title Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
title_full Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
title_fullStr Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
title_full_unstemmed Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
title_short Miller Fisher Syndrome Following Vaccination against SARS-CoV-2
title_sort miller fisher syndrome following vaccination against sars-cov-2
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038467/
https://www.ncbi.nlm.nih.gov/pubmed/35370249
http://dx.doi.org/10.2169/internalmedicine.8851-21
work_keys_str_mv AT yamakawamakoto millerfishersyndromefollowingvaccinationagainstsarscov2
AT nakaharakeiichi millerfishersyndromefollowingvaccinationagainstsarscov2
AT nakanishitoshihito millerfishersyndromefollowingvaccinationagainstsarscov2
AT nomuratoshiya millerfishersyndromefollowingvaccinationagainstsarscov2
AT uedamitsuharu millerfishersyndromefollowingvaccinationagainstsarscov2

Ejemplares similares